ReviewFrontiers in cell and developmental biology2026
The multifaceted roles of mesenchymal stem cell-derived exosomes in digestive system malignancies: mechanisms and therapeutic implications.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bone marrow mesenchymal stem cell-derived exosomal miR-93-5p suppresses esophageal squamous cell carcinoma progression and immune escape through targeting PD-L1.Translational cancer research · 2026Article
- Analysis and validation of abnormal signaling pathways and immune cell infiltration characteristics in digestive system cancers based on peroxisome-related genes.Biology direct · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cell-derived exosomes (MSC-Exos) have emerged as key mediators of intercellular communication within the tumor microenvironment. However, a comprehensive synthesis of their paradoxical roles in digestive system tumors remains absent. This review provides an in-depth analysis of the molecular mechanisms by which MSC-Exos regulate tumor progression, with a focus on how they transfer specific non-coding RNAs and proteins to target cells, thereby modulating angiogenesis, epithelial-mesenchymal transition, immune evasion, and drug resistance. We highlight the functional heterogeneity of MSC-Exos in colorectal, liver, gastric, and pancreatic cancers, and examine how signals from the tumor microenvironment remodel their molecular cargo, establishing complex feedback loops. Furthermore, we discuss emerging translational frontiers, including the engineering of MSC-Exos as targeted drug delivery vehicles. By integrating mechanistic insights with clinical challenges, this review aims to elucidate the complex biology of MSC-Exos and pave new avenues for their application in precision oncology for digestive system tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.